![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Lead-in Cohort Results From a Phase 2 Study of a Novel 8-week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients With Chronic Hepatitis C Virus Infection
|
|
|
European Association for the Study of the Liver (EASL) 2024 Congress, 5-8 June, Milan, Italy.
Alina Jucov,1 Brian Conway,2 Laura Iliescu,3 Paul Mitrut,4 Simin Florescu,5 Roxana Cernat,6 Elena Ermacicova,7 Shannan Lynch,8 Marina Majarian,8 Sergey Izmailyan,8 Xiao-Jian Zhou,8 Keith Pietropaolo,8 Bruce Belanger,8
Arantxa Horga,8 Qi Huang,8 and Janet Hammond8
1Arensia Exploratory Medicine GmbH and Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova; 2Vancouver Infectious Diseases Centre, Vancouver, Canada; 3Institutul Clinic Fundeni, Bucharest, Romania; 4University of Medicine and Pharmacy, Craiova, Romania; 5Spitalul Clinic Dr. Victor Babes, Bucharest, Romania; 6Clinical Hospital for Infectious Diseases, "Ovidius" University, Constanta, Romania; 7Arensia Exploratory Medicine GmbH, Chisinau, Moldova; 8Atea Pharmaceuticals, Inc., Boston, USA
![0613241](../images/061424/061424-18/0613241.gif)
![0613242](../images/061424/061424-18/0613242.gif)
![0613243](../images/061424/061424-18/0613243.gif)
![0613244](../images/061424/061424-18/0613244.gif)
![0613245](../images/061424/061424-18/0613245.gif)
![0613246](../images/061424/061424-18/0613246.gif)
![0613247](../images/061424/061424-18/0613247.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|